SEARCH

SEARCH BY CITATION

References

  • 1
    Smith RA, Cokkinides V, Brawley OW. Cancer screening in the United States, 2009: a review of current American Cancer Society guidelines and issues in cancer screening. CA Cancer J Clin 2009; 59: 2741.
  • 2
    Kovats S, Main EK, Librach C, Stubblebine M, Fisher SJ, DeMars R. A class I antigen. HLA-G, expressed in human trophoblasts. Science 1990; 248: 22023.
  • 3
    Paul P, Rouas-Freiss N, Khalil-Daher I, Moreau P, Riteau B, Le Gal FA, Avril MF, Dausset J, Guillet JG, Carosella ED. HLA-G expression in melanoma: a way for tumor cells to escape from immunosurveillance. Proc Natl Acad Sci USA 1998; 95: 451015.
  • 4
    Wiendl H, Mitsdoerffer M, Hofmeister V, Wischhusen J, Bornemann A, Meyermann R, Weiss EH, Melms A, Weller M. A functional role of HLA-G expression in human gliomas: an alternative strategy of immune escape. J Immunol 2002; 168: 477280.
  • 5
    Lefebvre S, Antoine M, Uzan S, McMaster M, Dausset J, Carosella ED, Paul P. Specific activation of the non-classical class I histocompatibility HLA-G antigen and expression of the ILT2 inhibitory receptor in human breast cancer. J Pathol 2002; 196: 26674.
  • 6
    Bukur J, Rebmann V, Grosse-Wilde H, Luboldt H, Ruebben H, Drexler I, Sutter G, Huber C, Seliger B. Functional role of human leukocyte antigen-G up-regulation in renal cell carcinoma. Cancer Res 2003; 63: 410711.
  • 7
    Urosevic M, Kurrer MO, Kamarashev J, Mueller B, Weder W, Burg G, Stahel RA, Dummer R, Trojan A. Human leukocyte antigen G up-regulation in lung cancer associates with high-grade, human histology, leukocyte antigen class I loss and interleukin-10 production. Am J Pathol 2001; 159: 81724.
  • 8
    Urosevic M, Willers J, Mueller B, Kempf W, Burg G, Dummer R. HLA-G protein up-regulation in primary cutaneous lymphomas is associated with interleukin-10 expression in large cell T-cell lymphomas and indolent B-cell lymphomas. Blood 2002; 99: 60917.
  • 9
    Nückel H, Rebmann V, Dürig J, Dührsen U, Grosse-Wilde H. HLA-G expression is associated with an unfavorable outcome and immunodeficiency in chronic lymphocytic leukemia. Blood 2005; 105: 16948.
  • 10
    Erikci AA, Karagoz B, Ozyurt M, Ozturk A, Kilic S, Bilgi O. HLA-G expression in B chronic lymphocytic leukemia: a new prognostic marker? Hematology 2009; 14: 1015.
  • 11
    Giannopoulos K, Dmoszyńska A, Bojarska-Junak A, Schmitt M, Roliński J. Expression of HLA-G in patients with B-cell chronic lymphocytic leukemia (B-CLL). Folia Histochem Cytobiol 2008; 46: 45760.
  • 12
    Yan WH, Lin A, Chen BG, Luo WD, Dai MZ, Chen XJ, Xu HH, Li BL. Unfavourable clinical implications for HLA-G expression in acute myeloid leukaemia. J Cell Mol Med 2008; 12: 88998.
  • 13
    Rouas-Freiss N, Moreau P, Menier C, LeMaoult J, Carosella ED. Expression of tolerogenic HLA-G molecules in cancer prevents antitumor responses. Semin Cancer Biol 2007; 17: 41321.
  • 14
    Rebmann V, Regel J, Stolke D, Grosse-Wilde H. Secretion of sHLA-G molecules in malignancies. Semin Cancer Biol 2003; 13: 3717.
  • 15
    Fournel S, Aguerre-Girr M, Huc X, Lenfant F, Alam A, Toubert A, Bensussan A, Le Bouteiller P. Cutting edge: soluble HLA-G1 triggers CD95/CD95 ligand-mediated apoptosis in activated CD8+ cells by interacting with CD8. J Immunol 2000; 164: 61004.
  • 16
    Singer G, Rebmann V, Chen YC, Liu HT, Ali SZ, Reinsberg J, McMaster MT, Pfeiffer K, Chan DW, Wardelmann E, Grosse-Wilde H, Cheng CC, et al. HLA-G is a potential tumor marker in malignant ascites. Clin Cancer Res 2003; 9: 44604.
  • 17
    Fukushima Y, Oshika Y, Nakamura M, Tokunaga T, Hatanaka H, Abe Y, Yamazaki H, Kijima H, Ueyama Y, Tamaoki N. Increased expression of human histocompatibility leukocyte antigen-G in colorectal cancer cells. Int J Mol Med 1998; 2: 34951.
  • 18
    Ye SR, Yang H, Li K, Dong DD, Lin XM, Yie SM. Human leukocyte antigen G expression: as a significant prognostic indicator for patients with colorectal cancer. Mod Pathol 2007; 20: 37583.
  • 19
    Pistoia V, Morandi F, Wang X, Ferrone S. Soluble HLA-G: are they clinically relevant? Semin Cancer Biol 2007; 17: 46979.
  • 20
    Torres MI, López-Casado MA, Luque J, Peña J, Ríos A. New advances in coeliac disease: serum and intestinal expression of HLA-G. Int Immunol 2006; 18: 71318.
  • 21
    Rebmann V, Pfeiffer K, Passler M, Ferrone S, Maier S, Weiss E, Grosse-Wilde H. Detection of soluble HLA-G molecules in plasma and amniotic fluid. Tissue Antigens 1999; 53: 1422.
  • 22
    Mapp CE, Ferrazzoni S, Rizzo R, Miotto D, Stignani M, Boschetto P, Maestrelli P, Baricordi OR. Soluble human leucocyte antigen-G and interleukin-10 levels in isocyanate-induced asthma. Clin Exp Allergy 2009; 39: 81219.
  • 23
    Rizzo R, Melchiorri L, Simone L, Stignani M, Marzola A, Gullini S, Baricordi OR. Different production of soluble HLA-G antigens by peripheral blood mononuclear cells in ulcerative colitis and Crohn's disease: a noninvasive diagnostic tool? Inflamm Bowel Dis 2008; 14: 1005.
  • 24
    Aractingi S, Kanitakis J, Euvrard S, Le Danff C, Carosella ED. Selective expression of HLA-G in malignant and premalignant skin specimens in kidney transplant recipients. Int J Cancer 2003; 106: 2325.
  • 25
    Hansel DE, Rahman A, Wilentz RE, Shih IEM, McMaster MT, Yeo CJ, Maitra A. HLA-G upregulation in pre-malignant and malignant lesions of the gastrointestinal tract. Int J Gastrointest Cancer 2005; 35: 1523.
  • 26
    Sturgeon C. Practice guidelines for tumor marker use in the clinic. Clin Chem 2002; 48: 11519.
  • 27
    Desch CE, Benson AB, III, Somerfield MR, Flynn PJ, Krause C, Loprinzi CL, Minsky BD, Pfister DG, Virgo KS, Petrelli NJ. Colorectal cancer surveillance: 2005 update of an American Society of Clinical Oncology practice guideline. J Clin Oncol 2005; 23: 851219.
  • 28
    Bast RC, Jr, Ravdin P, Hayes DF, Bates S, Fritsche H, Jr, Jessup JM, Kemeny N, Locker GY, Mennel RG, Somerfield MR. 2000 Update of recommendations for the use of tumor markers in breast and colorectal cancer: clinical practice guidelines of the American Society of Clinical Oncology. J Clin Oncol 2001; 19: 186578.
  • 29
    Ishida H, Miwa H, Tatsuta M, Masutani S, Imamura H, Shimizu J, Ezumi K, Kato H, Kawasaki T, Furukawa H, Kawakami H. Ki-67 and CEA expression as prognostic markers in Dukes' C colorectal cancer. Cancer Lett 2004; 207: 10915.
  • 30
    Fernandes CL, Kim SB, Matos D. Cytokeratins and carcinoembryonic antigen in diagnosis, staging, and prognosis of colorectal adenocarcinoma. World J Gastroenterol 2005; 11: 6458.
  • 31
    Duffy MJ, van Dalen A, Haglund C, Hansson L, Klapdor R, Lamerz R, Nilsson O, Sturgeon C, Topolcan O. Clinical utility of biochemical markers in colorectal cancer: European group on tumor markers (EGTM) guidelines. Eur J Cancer 2003; 39: 71827.
  • 32
    Carpelan-Holmstrom M, Louhimo J, Stenman UA, Alfthan H, Jarvinen H, Haglund C. Estimating the probability of cancer with several tumor markers in patients with colorectal disease. Oncology 2004; 66: 296302.